This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints, Permissions and Rights Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Alexopoulou, O. Articles by Maiter, D. Search for Related Content PubMed PubMed Citation Articles by Alexopoulou, O. Articles by Maiter, D. Related Collections Neuroendocrinology and Pituitary Endocrine Oncology

Divergence between Growth Hormone and Insulin-Like Growth Factor-I Concentrations in the Follow-Up of Acromegaly

Department of Endocrinology (O.A., D.M.), St. Luc University Hospital, Université Catholique de Louvain, B-1200 Brussels, Belgium; Department of Endocrinology (M.B.), Gasthuisberg University Hospital, Gasthuisberg, Katholieke Universiteit Leuven, B-3000, Leuven, Belgium; Department of Endocrinology (R.A.), University of Antwerp, B-2610 Antwerp, Belgium; Department of Endocrinology (G.T.), University Hospital of Gent, B-9000 Gent, Belgium; and Department of Endocrinology (B.V.), Academic Hospital Free University of Brussels, B-1090 Brussels, Belgium

Address all correspondence and requests for reprints to: Dr. O. Alexopoulou, Service d’Endocrinologie et Nutrition, Cliniques Universitaires St. Luc, Avenue Hippocrate 54, UCL 54.74, B-1200 Brussels, Belgium. E-mail: orsalia.alexopoulou{at}diab.ucl.ac.be.

Context: Divergence between GH and IGF-I values is regularly observed in treated acromegalic patients, and its significance is unclear.

Objectives: The objective of the study was to explore the frequency and identify potential determinants of discordant serum GH and IGF-I concentrations in noncured acromegalic patients.

Patients: Two hundred twenty-nine noncured acromegalic patients of the Belgian acromegaly registry (AcroBel) were grouped according to their mean GH level ( or > 2 µg/liter) and IGF-I z-score ( 2 or > 2). Clinical and metabolic parameters were compared between groups with active disease (high GH and IGF-I; n=81),high GH (with normal IGF-I; n=25), high IGF-I (with normal GH; n=55), and controlled disease (GH and IGF-I normal; n=68).

Results: Compared with the high IGF-I group, the high GH group was characterized by younger age (52 vs. 58 yr, P < 0.05), female predominance (72 vs. 36%, P < 0.01), and lower body mass index (25 vs. 31 kg/m²; P < 0.001), fasting glucose (91 vs. 99 mg/dl; P < 0.05), and glycated hemoglobin levels (5.7 vs. 6.1%; P < 0.01). There was no difference among the groups regarding baseline characteristics of pituitary adenoma, current medical treatment, or symptom score.

Conclusions: Thirty-five percent of noncured acromegalic patients exhibit a discordant GH and IGF-I pattern. The high GH phenotype was found predominantly in younger estrogen-sufficient females, implying a possible role for age, gender, and estrogens in this biochemical divergence. The high IGF-I phenotype was associated with a worse metabolic profile, suggesting that high IGF-I, rather than high GH, is indicative of persistently active disease.

This article has been cited by other articles:

				P. Kamenicky, C. Dos Santos, C. Espinosa, S. Salenave, F. Galland, Y. Le Bouc, P. Maison, P. Bougneres, and P. Chanson D3 GH receptor polymorphism is not associated with IGF1 levels in untreated acromegaly Eur. J. Endocrinol., August 1, 2009; 161(2): 231 - 235. [Abstract] [Full Text] [PDF]

				A. Bianchi, A. Giustina, V. Cimino, R. Pola, F. Angelini, A. Pontecorvi, and L. De Marinis Influence of Growth Hormone Receptor d3 and Full-Length Isoforms on Biochemical Treatment Outcomes in Acromegaly J. Clin. Endocrinol. Metab., June 1, 2009; 94(6): 2015 - 2022. [Abstract] [Full Text] [PDF]

				J. D. Carmichael, V. S. Bonert, J. M. Mirocha, and S. Melmed The Utility of Oral Glucose Tolerance Testing for Diagnosis and Assessment of Treatment Outcomes in 166 Patients with Acromegaly J. Clin. Endocrinol. Metab., February 1, 2009; 94(2): 523 - 527. [Abstract] [Full Text] [PDF]

				V J Moyes, K A Metcalfe, and W M Drake Clinical use of cabergoline as primary and adjunctive treatment for acromegaly Eur. J. Endocrinol., November 1, 2008; 159(5): 541 - 545. [Abstract] [Full Text] [PDF]